Javelin Biotech’s Post

New 3i Investigator Article Alert!! Modulation of Hepatic Functions by Chicory (Cichorium intybus L.) Extract: Preclinical Study in Rats https://lnkd.in/gPdhzXa9

It has been suggested that if a picture tells a thousand words, then may be a moving picture (video) is worth a million people (Going Social: The State of Video in 2013)! In any case, there is little doubt that many of us experience a true EUREKA! moment when sophisticated science is translated into a short and engaging video, so with that in mind, read on.. Depixus MAGNA™ technology brings a new biophysical, single-molecule technology to the world of RNA drug development, providing powerful new insights into how drugs modulate RNA structures for therapeutic benefit, helping to accelerate and de-risk drug discovery in this fast-emerging field. This video shows how MAGNA™ achieves that. This is but a tip of the iceberg, as the same approach can be used to reveal a broad range of complex biomolecular interactions in other exciting areas of drug discovery, and life science research as well. MAGNA™ is a powerful new technology to reveal biomolecular interactions, decode disease mechanisms and unlock faster routes to more effective therapies. Learn more at depixus.com. #drugdiscovery #rnatherapeutics #biotherapeutics #drugdevelopment #pharmainnovation

In the hallowed halls of the Princeton Hotel Crown Plaza, amidst the ongoing symposium of the esteemed Alcor 7th Drug Discovery Platform, Dr. Ravi Kumar, Founder & Chief Scientific Officer of Immunocure Inc, graces the stage with his profound insights. Topic: Illuminating AI-Driven Drug Discovery: AxDrug for Automated Lead Generation and Optimization Dr. Ravi Kumar Muttineni, the luminary behind Immunocure Discovery Solutions, stands as a beacon of innovation in the realm of early drug discovery. Through their avant-garde Contract Research Organization (CRO), empowered by the proprietary AI platform, AxDrug, Immunocure seamlessly integrates cutting-edge computational chemistry tools and a state-of-the-art synthetic chemistry lab. Pioneering advancements in lead molecule delivery, targeted protein degraders (TPDs), protein designing, and antibody engineering, Immunocure sets a new benchmark for innovation. Join us as we embark on a journey to redefine possibilities and unlock the latent potential of tomorrow's therapeutics alongside Dr. Ravi Kumar. This is an invitation to participate in the shaping of the future of drug discovery, where every molecule holds the promise of transformative impact. #ADDP2024 #7thADDP #Alcordrugdiscoveryplatform #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits  #DrugDiscoverySummits #EuropeanClinicalTrialSummits #Scientist #DrugDiscovery #Preclinical #Medchem #Biology #Protein #Antibodies #Conference #InPersonEvent #Summit #AI #ML #Data #Oncology #DrugDevelopment #Collaboration #Keynote #PanelDiscussion #Oncology #Therapeutics #DrugDesign #SmallMolecules #LargeMolecules #Events #Therapeutics #BigData #Marketing #DigitalMarketing #AIdrug #alcordrug #alcordiscovery #addp2024

Cellular in vitro models are crucial in preclinical research for understanding the pathologies and development of new drugs. However, due to the complex nature of the human body, obtaining accurate cell models can be difficult.   Tebubio, our European distributor, is delivering a webinar on the challenges of in vitro models, exploring the advantages of consolidating biological sample sourcing with a single, reliable partner, and sharing insights into the comprehensive solutions available for cultivating pertinent cellular models.   📅Tuesday 25th June 🕐10:00am BST | 11:00am CEST 💻Register here: https://rb.gy/3j3zel   #CellularResearch #InVitroModels #ResearchEfficiency

A systematic review of the local field potential adaptations during conditioned place preference task in preclinical studies https://lnkd.in/ey3zFxmM

Discover how organoids bridge the gap between the lab and clinic Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM BST to learn more about how patient-derived organoids are revolutionising drug discovery. https://lnkd.in/eEC865ka #Organoids #DrugDiscovery #LifeSciences HUB Organoids

🌟 Meet our new community member: Ary Marsee from HepX Predict! 🌱 Last week, we kicked off our Science and Life Science Validation program. Stay tuned as we introduce our incredible lineup over the coming weeks! HepX Predict is revolutionizing drug development with patented 3D liver organoid technology. By bridging the gap between pre-clinical studies and clinical success, they're tackling the challenge of drug failures head-on. With 70-80% of drugs failing in human trials due to ineffective preclinical models, and liver toxicity contributing to over 20% of these failures, the need for accurate in vitro models is more crucial than ever. Here's to a future of safer and more effective drugs! 💊✨ #DrugDevelopment #Innovation #LifeScience

The Spatial Biology for Drug Development Summit starts tomorrow. Meet with us there to learn how we can assist in all aspects of #biomarker research, from discovering new biomarkers to the development and support of their clinical use. https://hubs.la/Q023sHf50 #SpatialBiology

📺 [WEBINAR] 𝐍𝐚𝐧𝐨𝐁𝐑𝐄𝐓™ 𝐭𝐨 𝐐𝐮𝐚𝐧𝐭𝐢𝐟𝐲 𝐋𝐢𝐯𝐞 𝐂𝐞𝐥𝐥 𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐧𝐠𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐚𝐭 𝐑𝐀𝐒 𝐚𝐧𝐝 𝐢𝐭𝐬 𝐃𝐨𝐰𝐧𝐬𝐭𝐫𝐞𝐚𝐦 𝐄𝐟𝐟𝐞𝐜𝐭𝐨𝐫𝐬 📅 Wed, August 23, 2023 🕔 5pm CEST 👨🏫 Matt Robers, PhD, Senior Research Scientist and Group Leader, Promega 💊🎯 In this webinar, you will learn how: • NanoBRET™ TE assays broadly enable the quantitative determination of compound affinity/potency for specific targets inside cells; • Intracellular protein-protein interactions and target protein activation states have a strong influence on drug compound pharmacology, using RAS-MAPK as an example; • NanoBRET™ TE Assays can be used to connect structural features of inhibitors to their biophysical properties in a cellular system 🎟️ Registration: https://bit.ly/45bJP8h

The clinical development pipeline growth and investment in modalities such as cell and gene therapy, mRNA, radiopharmaceuticals, and antibody-drug conjugates (ADCs) have nearly doubled in the last five years. This growth, alongside scientific advances in data-driven tools, presents new possibilities for biotech drug development. While these advancements bring tremendous opportunities, they also come with complexity. Get the latest insights from our commercial strategists at Health Advances (A Parexel Company). Stay ahead of the curve in the dynamic landscape of clinical development. #ClinicalDevelopment #BiotechInvestment #ScientificAdvances #ParexelBiotech